Clinical Trial

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase and a LTE (Long Term Extension)
Protocol Amendment History 1 change
minor Completion pushed: 2027-03 -> 2028-03 2026-05-06
Trial Details
NCT Number NCT06109441
Lead Sponsor AltruBio Inc.
Conditions Ulcerative Colitis
Enrollment 50 participants
Start Date 2023-12-04
Primary Completion 2026-03-05 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-05